Resveratrol Lipodisq Sterile Solution
| Code | Size | Price |
|---|
| IAX-700-105-L001 | 1 ml | £197.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
AMBIENT
Storage:
Short term: +4°C. Long term: +4°C
Documents
Further Information
Alternate Names/Synonyms:
trans-3,4',5-Trihydroxystilbene; trans-Resveratrol; (E)-Resveratrol; 3,4',5-Stilbenetriol
Appearance:
Light amber coloured clear aqueous solution
Biological Activity:
Discoidal nano-particles can incorporate hydrophobic, poorly water-soluble compounds, such as lipids, lipoproteins and glycolipids. - Cell culture tested (human macrophage cell line) (MTT). - Recommended starting dilution: 1:200 or higher. - Optimal working concentrations depend on the applications and need to be determined. - Published procedures using Lipodisq formulations (Curcumin and IAXO TLR4 antagonists) in vivo rodent models at 3-10mg/kg. Recommended route of administration is subcutaneous (s.c.) with oral or nasal application as a possible alternative, which needs to be optimized.
CAS:
501-36-0
Concentration:
1mg/ml (0.1% w/vol)
EClass:
32160000
Form (Short):
liquid
Formulation:
Liquid, detergent-free discoidal nano-formulation made of styrene-maleic acid lipid particles (SMALP), lecithin and sterile water.
GHS Symbol:
GHS07
Handling Advice:
Keep sterile. Avoid skin and eye contact.
Hazards:
H315, H319, H335
InChi:
InChi=1S/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1+
InChiKey:
LUKBXSAWLPMMSZ-OWOJBTEDSA-N
Long Description:
Chemical. CAS: 501-36-0. Formula: C14H12O3. MW: 228.2. Resveratrol Lipodisq Sterile Solution is a ready-to-use nano-formulated aqueous solution. Potent phenolic antioxidant found in grapes and red wine. Eicosanoid synthesis and platelet aggregation inhibitor. Chemopreventive. Specific inhibitor of cyclooxygenase-1 (COX-1). Anti-inflammatory, anticancer and antiproliferative compound. Apoptosis and autophagy inducer. Potent SIRT1 (sirtuin 1) activator. Senescence modulator. Cardioprotective and neuroprotective. Adipogenesis inhibitor. Resveratrol Lipodisq is based on a nanoparticle (11-40nm) drug delivery system comprising a discoidal phospholipid bilayer membrane stabilized by a chaperone molecule annulus. Internal properties of the phospholipid membrane support the disposition and stabilization of drug molecule candidates and preserve the native conformation of membrane molecules. The resulting encapsulated actives are rendered water-soluble and specialized for intra-cellular penetration/delivery via endosomal uptake mechanisms. Lipodisq solutions show a good safety profile and are suitable for in vitro and in vivo investigations.
MDL:
MFCD00133799
Molecular Formula:
C14H12O3
Molecular Weight:
228.2
Other data:
Lipodisq™ technology is covered by one or more of the following patents owned by Malvern Cosmeceutics Limited: AU2006253886, CA2611144, CN101184473B, EP1890675, GB2426703, IN261468, JP5142898, US8623414 and WO/2021/005340A1 pending. The purchaser is licensed under those patents to use these assemblies for the purpose of research and development only, but not for the purpose of delivery of agents for clinical use to humans or veterinary use to animals for therapeutic, diagnostic or prophylactic purposes, which uses are specifically prohibited.
Package Type:
Vial
Precautions:
P261, P271, P280, P312
Product Description:
Resveratrol Lipodisq Sterile Solution is a ready-to-use nano-formulated aqueous solution. Potent phenolic antioxidant found in grapes and red wine. Eicosanoid synthesis and platelet aggregation inhibitor. Chemopreventive. Specific inhibitor of cyclooxygenase-1 (COX-1). Anti-inflammatory, anticancer and antiproliferative compound. Apoptosis and autophagy inducer. Potent SIRT1 (sirtuin 1) activator. Senescence modulator. Cardioprotective and neuroprotective. Adipogenesis inhibitor. Resveratrol Lipodisq is based on a nanoparticle (11-40nm) drug delivery system comprising a discoidal phospholipid bilayer membrane stabilized by a chaperone molecule annulus. Internal properties of the phospholipid membrane support the disposition and stabilization of drug molecule candidates and preserve the native conformation of membrane molecules. The resulting encapsulated actives are rendered water-soluble and specialized for intra-cellular penetration/delivery via endosomal uptake mechanisms. Lipodisq solutions show a good safety profile and are suitable for in vitro and in vivo investigations.
Purity:
>95% (HPLC)
Signal Word:
Warning
SMILES:
OC1=CC=C(C=CC2=CC(O)=CC(O)=C2)C=C1
Solubility Chemicals:
Soluble in water, PBS, Tris and other physiological solutions as formulated in a proprietary, thermostable, aqueous lipid nanoparticulate formulation (Lipodisq).
Transportation:
Non-Hazardous
UNSPSC Category:
Natural Products/Extracts
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 1 year after receipt when stored at +4°C.
References
Antiviral Activity of Resveratrol against Human and Animal Viruses: Y. Abba, et al.; Adv. Virol. 2015, 184241 (2015) | Can Resveratrol-Inhaled Formulations Be Considered Potential Adjunct Treatments for COVID-19? G.A. Rossi, et al.; Front. Immunol. 12, 670955 (2021) | Role of Resveratrol in Prevention and Control of Cardiovascular Disorders and Cardiovascular Complications Related to COVID-19 Disease: Mode of Action and Approaches Explored to Increase Its Bioavailability: N. Gligorijevic, et al.; Molecules 26, 2834 (2021) | Resveratrol and Pterostilbene Inhibit SARS-CoV-2 Replication in Air?Liquid Interface Cultured Human Primary Bronchial Epithelial Cells: B.M. Ter Ellen, et al.; Viruses 13, 1335 (2021) | COVID-19: immunopathology, pathophysiological mechanisms, and treatment options: L.E. Van Eijk, et al.; J. Pathol. 254, 307 (2021) | Targeting Multiple Signal Transduction Pathways of SARS-CoV-2: Approaches to COVID-19 Therapeutic Candidates: S. Fakhri, et al.; 26, 2917 Molecules (2021) | Bioactivity, bioavailability, and gut microbiota transformations of dietary phenolic compounds: implications for COVID-19: P.R. Augusti, et al.; J. Nutr. Biochem. 97, 108787 (2021) | Resveratrol as an Adjunctive Therapy for Excessive Oxidative Stress in Aging COVID-19 Patients: M.-T. Liao, et al.; Antioxidants 10, 1440 (2021) | A comprehensive guide to the pharmacologic regulation of angiotensin converting enzyme 2 (ACE2), the SARS-CoV-2 entry receptor: M. Oz, et al.; Pharmacol. Ther. 221, 107750 (2021) | Molecular Mechanisms of Possible Action of Phenolic Compounds in COVID-19 Protection and Prevention: N. Gligorijevic, et al.; Int. J. Mol. Sci. 22, 12385 (2021) | Therapeutic Potential of Resveratrol in COVID-19-Associated Hemostatic Disorders: R. Giordo, et al.; Molecules 26, 856 (2021) | The Importance of Nutraceuticals in COVID-19: What?s the Role of Resveratrol? E. Domi, et al.; Molecules 27, 2376 (2022) | COVID-19: Immunology, Immunopathogenesis and Potential Therapies: A. Bhardwaj, et al.; Int. Rev. Immunol. 41, 171 (2022) | General References for Lipodisq™ Technology: | Responsive Hydrophobically Associating Polymers: A Review of Structure and Properties: S.R. Tonge & B.J. Tighe; Adv. Drug Deliv. Rev. 53, 109 (2001) | Detergent-free formation and physico-chemical characterization of nanosized lipidpolymer complexes: Lipodisq; M.C. Orwick, et al.; Angew. Chem. 51, 4653 (2012) | Physicochemical Characterization, Toxicity and In Vivo Biodistribution Studies of a Discoidal, Lipid-Based Drug Delivery Vehicle: Lipodisq Nanoparticles Containing Doxorubicin: M.L. Torgersen, et al.; J. Biomed. Nanotechnol. 16, 41 (2020) | Applications of Synthetic Polymer Discoidal Lipid Nanoparticles to Biomedical Research: M. Tanaka; Chem. Pharm. Bull. 70, 507 (2022) | Mechanisms of Formation, Structure, and Dynamics of Lipoprotein Discs Stabilized by Amphiphilic Copolymers: A Comprehensive Review: P.S. Orekhov, et al.; Nanomaterials 12, 361 (2022)